Pivotal Study of Sebacia Microparticles in the Treatment of Acne Vulgaris

Inclusion Criteria: * Males and females, 15 - 45 years of age * Able to provide informed consent/assent; minors will provide assent while parent or legal guardian will provide consent * Moderate to moderately severe (3 or 4) inflammatory acne vulgaris by Investigator's Global Assessment * Subject has 25 to 75 inflammatory lesions on the cheeks, chin and forehead, not concentrated in one area * Subject has Fitzpatrick skin phototype I, II or III * Subject is in good health, willing to participate and able to comply with protocol requirements Exclusion Criteria: * Severe acne (Investigator's Global Assessment 5) with significant scarring potential and greater than 2 nodular lesions * Clinically relevant history of keloids * Facial tattoos * Acne conglobata, acne fulminans, chloracne, drug-induced acne * Active concomitant skin disease, excessive scarring or excess facial hair * Heavily tanned skin; unable or unwilling to avoid tanning beds/excessive sun exposure * Acne medication and therapy restrictions - time period prior to Baseline (below) 1. Oral retinoids - 6 months 2. Other systemic medications - 4 weeks 3. Topical retinoids, steroids, antibiotics - 2 weeks 4. OTC topical treatments - 1 week 5. Light treatments (including IPL or laser), microdermabrasion and/or peels - 8 weeks 6. Investigational drug, biologic or device - 30 days 7. Gold therapy of any type for any reason - EXCLUDED * Pregnant, lactating, nursing or planning to become pregnant during the study period * Known allergy to gold, ethanol, diisopropyl adipate, Polysorbate 80 * Clinically relevant condition that makes participation unsafe or that would interfere with study treatment and assessment